Head and Neck Cancer
A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer
The reason for this study is to see if the study drug selpercatinib is safe and more effective compared to a standard treatment in participants with rearranged during transfection (RET)-mutant medullary thyroid cancer (MTC) that cannot be removed by surgery or has spread to other parts of the body.
Your participation in this trial could last approximately 30 months, depending on your cancer type and how you and your tumor respond.
Key Participation Requirements
All clinical trials have rules about who can participate. This section outlines some of those rules. Please contact a study center to discuss the full set of criteria
-Participants must have medullary thyroid cancer that is not able to be removed by surgery or has spread to other places in the body, has not been treated with certain medications previously, and has evidence on imaging studies that the cancer has gotten bigger in the previous 14 months
-Participants must have evidence that their cancer is caused by a mutation in the RET gene
-Participants must be in fair to good general health and not have another serious medical condition
-Participants must be willing to use highly effective contraception during the study
-Participants must not have cancer that has spread to the brain or spinal cord that is causing symptoms
-Participants must not have a heart condition that puts you at risk for abnormal heart rhythms